

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C.20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 26, 2007**

**ACCESS PHARMACEUTICALS, INC.**

---

(Exact name of registrant as specified in its charter)

**Delaware**

**0-9314**

**83-0221517**

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

**2600 Stemmons Freeway, Suite 176**  
**Dallas, Texas**

**75207**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

**(214) 905-5100**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;  
APPOINTMENT OF PRINCIPAL OFFICERS.**

(a) Effective December 19, 2007, Stephen R. Seiler resigned as President and Chief Executive Officer of the Company and concurrently resigned from the Company's Board of Directors.

(b) On December 26, 2007, the Company announced that Jeffrey B. Davis, 44, has been named by the Board of Directors as the Company's Chief Executive Officer effective as of December 26, 2007.

Mr. Davis became a director in March 2006. Mr. Davis is Chairman of the Board, member of the Executive Committee and a Chairman of the Compensation Committee of the Board. Mr. Davis currently serves as President of SCO Financial Group LLC. Previously, Mr. Davis served in senior management at a publicly traded healthcare technology company. Prior to that, Mr. Davis was an investment banker with various Deutsche Bank banking organizations, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff, and at Philips Medical Systems North America. Mr. Davis is currently on the board of MacroChem Corporation, Uluru, Inc. and Virium Pharmaceuticals, Inc., a private biotechnology company. Mr. Davis holds a B.S. in biomedical engineering from Boston University and an M.B.A. degree from the Wharton School, University of Pennsylvania.

Mr. Davis is a director of Somanta Pharmaceuticals, Inc. On April 19, 2007, we announced we had entered into an agreement to acquire Somanta Pharmaceuticals, Inc., pursuant to the terms of the merger agreement, upon consummation of the acquisition, Somanta's preferred and common shareholders will receive an aggregate of 1.5 million shares of Access' common stock

SCO Financial Group is an affiliate of SCO Capital Partners LLC. SCO Capital Partners LLC previously served as placement agent in conjunction with the Company's issuance of Series A Cumulative Convertible Preferred Stock. In exchange for its services as placement agent SCO Capital Partners LLC received a warrant to purchase 100,000 shares of Access common stock.

**ITEM 7.01 REGULATION FD DISCLOSURE**

A copy of the press release issued by us on December 26, 2007 announcing the appointment Mr. Davis as Chief Executive Officer is filed as Exhibit 99.1 and is incorporated by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits

<u>Number</u>	<u>Title</u>
99.1	Press Release dated December 26, 2007 entitled "Access Pharmaceuticals Appoints Jeffrey B. Davis As CEO"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCESS PHARMACEUTICALS, INC.  
(Registrant)

By: /s/ Stephen B. Thompson

---

Stephen B. Thompson  
Vice President, Chief Financial Officer

Date: December 26, 2007

---

**Exhibit Index**

**Exhibit No.**

**Description**

99.1 Press release issued by Access Pharmaceuticals, Inc. dated December 26, 2007.

---

{Access Letterhead}  
**ACCESS NEWS**

**Contact: Company**

**Stephen B. Thompson**  
 Vice President, Chief Financial Officer  
 Inc.  
 (214) 905-5100

**Contact: Investor Relations**

Steinberg (media)  
 Weinberger Assoc. LLC  
 Access Pharmaceuticals,

Access Pharmaceuticals

(212) 732-4300

**Donald C. Weinberger/Alisa**

**Wolfe Axelrod**

(212) 370-4500

**Andrew Hellman, CEOcast, Inc. for**

**ACCESS PHARMACEUTICALS APPOINTS JEFFREY B. DAVIS AS CEO  
 - Stephen R. Seiler Resigns as President and CEO -**

**DALLAS, TX, December 26, 2007, Access Pharmaceuticals, Inc. (OTC BB: ACCP)** announced today that current Chairman Jeffrey B. Davis has been appointed to the additional role of CEO. Stephen R. Seiler has resigned as President and CEO of the Company for health reasons. Mr. Seiler has also resigned from the Board of Directors.

"I believe that Access has an exciting future with ProLindac™, MuGard™, and the Cobalamin Vitamin B-12 oral delivery technology. The Company is positioned well for 2008 to be an eventful year. Access has been a rewarding experience and I am proud of what has been achieved during the past year," noted Mr. Seiler.

The Board of Directors has appointed Jeffrey B. Davis, the Chairman of the Board, as the CEO. Mr. Davis said, "On behalf of the Board of Directors and the entire Access team, I want to thank Steve for his efforts and achievements at Access this year, including the continued clinical development of ProLindac, a signing of a European partnership for MuGard, and the recently completed financing." Mr. Davis added, "I am excited about Access' prospects in 2008 and beyond, and look forward to working with the organization to build on recent achievements. Key among them is the continued development of our novel DACH platinum ProLindac, which is in a Phase 2 trial and will initiate multiple additional clinical trials next year, to complete ongoing partnering efforts and seek new partners for ProLindac, MuGard, and Cobalamin-enhanced products and platforms, and to actively expand our shareholder base."

---

**About Access:** Access Pharmaceuticals, Inc. is a biotechnology company that leverages its proprietary nano-polymer chemistry expertise to develop proprietary products. Access' products include ProLindac™, a novel DACH platinum drug that is currently in Phase 2 clinical testing of patients with ovarian cancer and MuGard™ for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery. Access has announced the execution of a definitive merger agreement to acquire Somanta. The acquisition of Somanta has not yet closed and the closing is subject to numerous closing conditions. For additional information on Access Pharmaceuticals, please visit our website at [www.accesspharma.com](http://www.accesspharma.com).

**-More-**

---

**About ProLindac™:** ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of \$2 billion.

*This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: the identification of a new CEO, clinical trial plans and results for ProLindac, the execution of license agreements in the future, our ability to raise additional funds and our ability to obtain or meet the closing conditions in the merger agreement with Somanta Pharmaceuticals, Inc. and applicable regulatory and tax requirements, and to otherwise complete the merger in a timely manner; yet there can be no assurances that the closing conditions will be met or waived or that the transaction will close. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' and Somanta's Annual Reports on Form 10-KSB and other reports filed by Access and Somanta with the Securities and Exchange Commission.*

###

---

